Akebia Initiates Phase 2 Trial For Ebribafusp
Akebia starts phase 2 trial for kidney disease treatment
Story updates
12:01:43 PM UTC
SquawkNews
AKBA - Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.